X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Poster session III * Friday 10 December 2010, 08:30-12:30
    Oxford University Press (OUP) ; 2010
    In:  European Journal of Echocardiography Vol. 11, No. Supplement 2 ( 2010-12-07), p. ii89-ii119
    Details
    In: European Journal of Echocardiography, Oxford University Press (OUP), Vol. 11, No. Supplement 2 ( 2010-12-07), p. ii89-ii119
    Type of Medium: Online Resource
    ISSN: 1525-2167 , 1532-2114
    URL: Article
    DOI: 10.1093/ejechocard/jeq144
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2010
    detail.hit.zdb_id: 2042482-6
    detail.hit.zdb_id: 2647943-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 2
    Online Resource
    Online Resource
    Multi analyte sensing of amphiphilic tridentate bis(benzimidazolyl)pyridine incorporated in liposomes and potential application in enzyme assay
    Royal Society of Chemistry (RSC) ; 2022
    In:  Analytical Methods Vol. 14, No. 24 ( 2022), p. 2357-2367
    Details
    In: Analytical Methods, Royal Society of Chemistry (RSC), Vol. 14, No. 24 ( 2022), p. 2357-2367
    Abstract: A liposome based nanosensor Lipo-1 for efficient detection of copper, cyanide (CN − ) and ATP in a pure aqueous medium has been described. Lipo-1 shows a fluorescence ON–OFF response with copper. However, Lipo-1.Cu (Lipo-1 and copper ensemble) was used for the OFF–ON detection of ATP with nM and CN − with μM detection levels, lower than the WHO permissible level for safe drinking. Lipo-1 has better and enhanced binding properties over the counter organic amphiphilic compound Bzimpy-LC, which is not soluble in water. The significant changes in the emission spectra in the presence of Cu 2+ , CN − and ATP ions, as variable inputs, are used to construct INHIBIT and OR logic operations in a nano-scale environment. The fluorescent detection of CN − ions with Lipo-1.Cu was used to develop an enzyme assay for β-glucosidase using amygdalin as the substrate. β-Glucosidase enzymatic activity was monitored by the emission OFF–ON signal of the probe Lipo-1.Cu by CN − detection. This approach could be an efficient method for developing a fluorescence-based β-glucosidase enzyme assay. A switch ON luminescence response, low detection limit, fast response, 100% aqueous solution, biocompatibility, multi-analyte detection, and improved sensitivity and selectivity of Bzimpy-LC in lipid bilayer membranes are the main features of the nanoprobe Lipo-1. These properties give it a clear advantage for analytical applications.
    Type of Medium: Online Resource
    ISSN: 1759-9660 , 1759-9679
    URL: Article
    DOI: 10.1039/D2AY00486K
    Language: English
    Publisher: Royal Society of Chemistry (RSC)
    Publication Date: 2022
    detail.hit.zdb_id: 2515210-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 3
    Online Resource
    Online Resource
    Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction
    Oxford University Press (OUP) ; 2013
    In:  Europace Vol. 15, No. 9 ( 2013-09-01), p. 1287-1291
    Details
    In: Europace, Oxford University Press (OUP), Vol. 15, No. 9 ( 2013-09-01), p. 1287-1291
    Type of Medium: Online Resource
    ISSN: 1099-5129 , 1532-2092
    URL: Article
    DOI: 10.1093/europace/eut045
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 2002579-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 4
    Online Resource
    Online Resource
    Impact of FDG-PET scan on follow-up care in nonmetastatic breast cancer
    American Society of Clinical Oncology (ASCO) ; 2009
    In:  Journal of Clinical Oncology Vol. 27, No. 15_suppl ( 2009-05-20), p. e11611-e11611
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 27, No. 15_suppl ( 2009-05-20), p. e11611-e11611
    Abstract: e11611 Background: Fluorine-18-FDG positron emission tomography (FDG-PET) role in the follow up care of non-metastatic breast cancer is not defined. Methods: We retrospectively analyzed 177 patients with stage I-III breast cancer between November 2004 and June 2006. IRB approval was obtained for this study. Patients were divided into two groups. Group A consisted of patients who had one or more FDG-PET scans as part of their clinical follow up (N=68), and Group B consisted of patients who did not (N=109). Clinical, radiological and pathology data were obtained from patients’ records. Results: Median follow-up is 35 months. Mean age 53 years for group A and 57 years for group B. Group A patients were more likely to have had higher stages (29% stage I, 53% stage II, and 18% stage III) compared with group B (64 % stage I, 31% stage II and 4% stage III). The two groups did not differ significantly in ER+ status (69% vs. 78% p=0.21), or Her2neu status (19% vs. 17%; p=0.6). Group A patients had more clinic visits (18 vs. 11; p=0.009), their tumor marker was checked more often (13 vs. 9 times; p=0.0001), had more radiological studies (10 studies vs. 5; p=0.0001), and had more biopsies (0.88 vs. 0.48 biopsy per patient; p=0.05). These differences were significant even after controlling for stage and chemotherapy. 9/68 patients in group A had tumor recurrence compared to 1/109 in group B (p=0.0003). PET scan indications were as follows: 29 (43%) for asymptomatic follow up evaluation [2 recurred] ; 18 (26%) concerning symptoms [0 recurred]; 10 (15%) elevated tumor marker [2 recurred] ; 7 (10%) other abnormal imaging studies [1 recurred]; 4 (6%) metastatic workup. Conclusions: While FDG-PET might aid in detecting recurrence in some patients with non-metastatic breast cancer, its use was associated with more clinic visits, blood tests, biopsies, and radiological tests. No significant financial relationships to disclose.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2009.27.15_suppl.e11611
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2009
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 5
    Online Resource
    Online Resource
    Significance of MTHFR gene mutation with normal homocysteine level in vascular events
    American Society of Clinical Oncology (ASCO) ; 2009
    In:  Journal of Clinical Oncology Vol. 27, No. 15_suppl ( 2009-05-20), p. e20520-e20520
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 27, No. 15_suppl ( 2009-05-20), p. e20520-e20520
    Abstract: e20520 Background: Hyperhomocysteinemia, due to a combination of genetic and environmental factors, is considered to be a risk factor for vascular disease. Two common variations of the MTHFR gene (C677T and A1298C) result in amino acid substitutions and enhanced thermolability of the enzyme. Individuals with MTHFR gene mutations appear to have raised plasma level of homocysteine which may lead to increased risk of vascular events. However, significance of MTHFR gene mutations with normal homocysteine levels is unknown. Objective: To assess the relation of MTHFR gene mutations with normal homocysteine level and risk of Vascular events (deep venous thrombosis (DVT), pulmonary embolism (PE), Ischemic Heart disease (IHD), cerebrovascular accidents (CVA),recurrent fetal loss). Methods: We reviewed the records of 90 patients referred to our benign hematology clinic for thrombophilia evaluation between 2006 and 2008. All available medical history for risk factors and laboratory test results, obtained from first vascular event through time of consultation, including genetic testing, were reviewed. Anti-cardiolipin antibody, MTHFR genotyping and Protein C and Protein S assays were performed at Warde Medical Laboratory, Ann Arbor, MI. Results: 61 patients with documented vascular events were tested for MTHFR gene mutations. Forty one of these patients also had homocysteine levels available. Thirty-eight of these 41 (92 %) patients had an MTHFR gene mutation with normal homocysteine levels. Eighteen (47%) of these 38 patients had only an MTHFR gene mutation with normal homocysteine level and no other congenital or acquired risk factors for vascular events identified. Conclusions: In our clinic population, many patients with documented vascular events had MTHFR gene polymorphisms with normal homocysteine levels with no other thrombophilia risk factors identified, raising the question of whether MTHFR gene polymorphisms alone, without hyperhomocysteinemia, may somehow contribute to thrombophilia. [Table: see text] No significant financial relationships to disclose.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2009.27.15_suppl.e20520
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2009
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 6
    Online Resource
    Online Resource
    Abstract P3-10-08: Breast cancer in octogenarians: Presentation and treatment affect mortality
    American Association for Cancer Research (AACR) ; 2018
    In:  Cancer Research Vol. 78, No. 4_Supplement ( 2018-02-15), p. P3-10-08-P3-10-08
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 4_Supplement ( 2018-02-15), p. P3-10-08-P3-10-08
    Abstract: Background: Breast cancer incidence increases in age. Unfortunately, elderly patients are often under-treated and under-diagnosed affecting their overall survival with limited availability of clinical trial data. Patients and Methods: We used data from our cancer registry and our state cancer registry to evaluate cases of breast cancer diagnosed between the years 2005 and 2010 with follow up data available to date to examine the method of diagnosis (mammogram vs. palpable abnormality), age at diagnosis, stage at diagnosis, type of surgery, receptor status, treatment received, and survival. We then were able to use our state database which contained data regarding causality of death. Based on the data available we were able to evaluate the impact of the method of diagnosis and treatment on patient mortality. Results: A total of 495 octogenerian breast cancer patients were diagnosed between 2005 and 2010. The median age at diagnosis was 85 with a range of 81-102. Out of the 495 patients 55% were diagnosed with a mammogram and 41% by palpable abnormality. The patients who presented with a palpable mass were more likely to die of breast cancer (26%) than the patients who presented with a screening abnormality (9%). The patients with a screening abnormality also had a longer survival (30.0 month) among patients who died from breast cancer as opposed to those who presented with a palpable abnormality who died from breast cancer (16.7 months). While the number of patients dying from other causes was similar (65% screened vs. palpable) the patients with palpable findings had a shorter survival (30.5 months) compared to those detected by screening (48.9 months). Table 1: Comparison of outcomes between screen detected and physical exam detected breast cancer patientsOutcomeScreenedPalpableDied of Breast Cancer9% (30.0 months)26% (16.7 months)Died of Other Causes65% (48.9 months)60% (30.5 months)Still Alive25.6% (66.9 months)10% (51.0 months) There was an improvement in survival among patients who presented with a palpable mass and were treated with endocrine therapy (17.3 vs 11%). This improvement did not extend to the screened population (24.3% vs 29%), although the patients who died from breast cancer had an overall longer survival (35.4 months vs 27.3 months). There was also an improvement in survival among patients who received radiation therapy in both the screened (33% vs. 22%) and palpable (22.5% vs 11.1%) groups. Only 6% of patients in the entire study received chemotherapy. Effect of presentation and treatment on survivalModalityScreened/TreatedPalpable/TreatedScreened/ No TreatmentPalpable/No TreatmentRadiation33% (29.6 months)22.5% (10 months)22% (27 months)11.1% (20 months)Endocrine24.3% (35.4 months)17.3% (15.7 months)29% (27.3 months)11% (18.5 months) Conclusion: Our data support continued use of screening mammography in patients who are at good surgical risk into their 80's. The patients who were diagnosed with symptoms fared worse than the patients who had their cancer discovered on routine imaging. There was an improvement in patients who were treated with adjuvant endocrine and radiation therapy although the rationale behind providing or excluding treatment cannot be discerned from this retrospective registry study. Citation Format: Wilson JP, Gadiyaram V, Blumencranz PW. Breast cancer in octogenarians: Presentation and treatment affect mortality [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-10-08.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.SABCS17-P3-10-08
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 7
    Online Resource
    Online Resource
    Predominance of Brain and Lung Metastases in Triple-Negative Breast Cancer Patients.
    American Association for Cancer Research (AACR) ; 2009
    In:  Cancer Research Vol. 69, No. 24_Supplement ( 2009-12-15), p. 6159-6159
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 24_Supplement ( 2009-12-15), p. 6159-6159
    Abstract: Background: Patients with triple-negative breast cancer have an increased likelihood of recurrence compared to other types of breast cancer, however, little is known about their pattern of metastatic spread. Our object was to evaluate the metastatic patterns of women diagnosed with triple-negative breast cancer compared to other subtypes. Methods: We studied a cohort of 572 white patients diagnosed with invasive breast cancer at West Virginia University Hospital between 1999 and 2004. Hospital registry, charts, and pathology records provided clinical data including tumor receptor status and biopsy-proven metastatic spread to bone, brain, liver and lung. Breast cancers that were negative for estrogen, progesterone, and HER2neu, otherwise known as triple-negative were compared with HER2neu-postive and HER2neu-negative (endocrine receptor positive) disease. Body mass index was calculated and a value of ≥30 considered indicative of obesity. Specimens of primary carcinoma were available for analysis of Ki67 mitotic index and expression of p53. Results: 134/572 (23.4%) had triple-negative breast cancer, while the frequencies were 108/572 (18.9%) and 330/572 (57.7%) in HER2neu-positive and HER2neu-negative (endocrine receptor positive) groups. Women with triple-negative disease were more likely to have brain-metastasizing breast cancer; 10.5% versus 4.6% for HER2neu-positive and 3.3% for HER2neu-negative (P & lt;0.05). They were also more likely to have metastasis to the lung; 10.5% versus 2.8% for HER2neu-positive and 7.0% for HER2neu-negative (P & lt;0.05). Triple-negative breast cancer patients who developed brain and lung metastases were younger & lt;50 years and significantly more obese (P=0.0236). High Ki67 labeling index and p53 expression were associated with more advanced disease indicating an aggressive phenotype for this group.Patterns of metastasis in breast cancer subtypesSite of metastasisTriple-negativeHER2-positiveHER2-negativeP valueBone20/134 (14.9)7/108 (6.5)38/330 (11.5)0.1037Brain14/134 (10.5)5/108 (4.6)11/330 (3.3)0.0136*Liver11/134 (8.2)4/108 (3.7)22/330 (6.7)0.3261Lung14/134 (10.5)3/108 (2.8)23/330 (6.9)0.0507*Other5/134 (3.7)3/108 (2.8)3/330 (0.91)0.1093 Conclusion: The excess risk of brain and lung metastasis in women with triple-negative breast cancers versus other subtypes needs further validation. The unique biology of triple-negative tumors may explain this pattern of metastatic spread. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6159.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS-09-6159
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 8
    Online Resource
    Online Resource
    Recurrence and survival after pulmonary metastasis in triple-negative breast cancer.
    American Society of Clinical Oncology (ASCO) ; 2010
    In:  Journal of Clinical Oncology Vol. 28, No. 15_suppl ( 2010-05-20), p. 1131-1131
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 28, No. 15_suppl ( 2010-05-20), p. 1131-1131
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2010.28.15_suppl.1131
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2010
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 9
    Online Resource
    Online Resource
    Abstract PD09-03: Disease Outcomes in Primary Breast Cancer Are Associated with Obesity, Lymph Node Status and Angiolymphatic Invasion
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 24_Supplement ( 2010-12-15), p. PD09-03-PD09-03
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 24_Supplement ( 2010-12-15), p. PD09-03-PD09-03
    Abstract: Background: Obesity is associated with higher rates of breast cancer and poorer survival. Our previous work has shown that lymph node metastases are more frequently associated with advanced disease in obese patients. We sought to investigate the association of obesity with angiolymphatic invasion on disease outcomes in patients with invasive breast cancer. Methods: This retrospective study involved 627 predominately white women with invasive breast cancer. Hospital tumor registry, charts, and pathology records provided demographics and tumor biologic features. Body mass index (BMI) values were categorized according to WHO criteria: normal or underweight (lean), & lt; 25.0 kg/m2; overweight, 25.0 to 29.9 kg/m2; obese, 30.0 kg/m2 or higher. Univariate and multivariate analyses were conducted between BMI and clinical outcomes, controlling for menopausal status. Recurrence-free survival and overall survival were calculated and a log-rank test was used to determine significance between groups. Results: In our study cohort, 175 (27.9%) were normal weight, 211 (33.7%) overweight and 241 (38.4%) were considered obese. Greater lymph node involvement and angiolymphatic invasion (P = 0.04) were present with obesity. Triple-negative tumors were more common in those patients classified as overweight and obese (43%) compared to normal weight individuals (20%). Factors associated with BMI were tumor size and lymph node status. In postmenopausal women, obesity was associated with an increased risk of lymph node metastases (OR 1.81, 95% CI 1.14-2.91; P = 0.010) and angiolymphatic invasion (OR 2.09, 95% CI 1.01-4.72; P = 0.049) when compared with normal weight individuals. The probability of developing a relapse within 10 years was higher among women with BMI ≥30.0 with positive lymph nodes and the presence of angiolymphatic invasion. Conclusions: In obese women with breast cancers, higher rates of lymph node involvement and angiolymphatic invasion may explain poorer outcomes. These findings further support the relationship between obesity and the factors that are elaborated by adipocytes as instrumental in promoting a more aggressive growth and progression of breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD09-03.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS10-PD09-03
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 10
    Online Resource
    Online Resource
    Phase II study of combined modality treatment for patients with potentially curable esophageal carcinoma
    American Society of Clinical Oncology (ASCO) ; 2008
    In:  Journal of Clinical Oncology Vol. 26, No. 15_suppl ( 2008-05-20), p. 15602-15602
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 26, No. 15_suppl ( 2008-05-20), p. 15602-15602
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2008.26.15_suppl.15602
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2008
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages